According to an Australian Broadcasting Corporation (ABC) report, the Commonwealth Scientific and Industrial Research Organisation (CSIRO) has been working for the last five years developing a safety test for induced pluripotent (iPS) stem cells.
CSIRO's Andrew Laslett said there were still a number of question marks about the long term stability and safety of iPS cells, which do not require a human embryo and are considered an important research advance.
"Sometimes the cells that are made from the iPS cells change back into stem cells which are unwanted because these cells can form tumours called teratomas," he said.
"At this stage it appears that human embryonic stem cells may be slightly safer, but it's early days," Laslett said.
"Any cell line that's going to be used for cell therapy has to go through a whole barrage of different tests to see whether they're safe," he said.
"We hope that this one will be added to that number of tests," he added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
